TABLE 2.

The single nucleotide polymorphisms (SNPs) found to be significant associated with an individual clearing infection via basic association analysis. Association tests were used to determine the genotype significantly associated with PZQ efficacy using PLINK; these are listed below each genetic model. The frequency of the allele/genotype for each model is listed, with the frequency separated by treatment outcome.

Enzyme	SNP	MAF (%)		Genotypic association							Allelic association				Cochran-armitage trend				Dominant model				Recessive model
				P			Genotype	AA vs. aA vs. aa			χ2 test		A vs. a		T2 test		A vs. a		χ2 test		aA + AA vs. aa		χ2 test		AA vs. aa + aA
		NC	C	DF	FE	χ2		P	NC	C	DF	P	NC	C	DF	P	NC	C	DF	P	NC	C	DF	P	NC	C
CYP1A2	rs951840747	2.632	7.456	1	0.018	0.010	CT	0.010 *	0/6/51	0/17/40	1	0.016 *	6/108	17/97	1	0.010	6/108	17/97	1	0.010*	6/51	17/40	1	NA	0/57	0/57
							TT	NA
CYP2D6	rs28371702	40.351	35.326	2	0.031	0.047	AC	0.014 *	37/18/2	25/31/1		0.089	92/22	81/33		0.061	92/22	81/33		0.559	55/2	56/1		0.024*	37/20	25/32
							CC	0.024 *
CYP3A5	rs1039108105	2.632	6.579	1	0.052	0.030	GC	0.030	0/6/51	0/15/42		0.039	6/108	15/99		0.030	6/108	15/99		0.030	6/51	15/42		NA	0/57	0/57
							CC	NA
	rs6976017	9.211	10.965	2	0.041	0.045	GA	0.050	3/15/39	0/25/32		0.509	21/93	25/89		0.489	21/93	25/89		0.176	18/39	25/32		0.079	3/54	0/57
							AA	0.079

Bold indicates the SNP genotype that were determined to be significantly associated with PZQ efficacy. The significance threshold is a p ≤ 0.05, with the * indicating a P _adj ≤ 0.05 obtained from χ² _Yates test representing an adjusted p-value accounting for a continuity correction.

FE, Fishers Exact Test; CYP, Cytochrome P450 enzyme; NC, Not cleared group; C, Cleared group.